Digital pathology market seen hitting $5.23B by 2035

Market Research Future projects the global digital pathology market will grow from $1.96 billion in 2025 to $5.23 billion by 2035, driven by pathologist shortages, primary-diagnosis clearances and reimbursed telepathology. North America leads today, while Asia-Pacific is expected to post the fastest growth through 2035.

Why it matters: - The digital pathology market is moving from niche imaging to core clinical infrastructure. - Growth is being driven by staffing pressure, reimbursement changes and broader regulatory acceptance of whole-slide imaging for primary diagnosis. - The shift matters for hospitals, reference labs, drug developers and software vendors because digitized pathology can expand capacity without adding headcount.

What happened: - Market Research Future projects the global digital pathology market will rise from USD 1.96 billion in 2025 to USD 5.23 billion by 2035. - The forecast implies a 10.4% compound annual growth rate from 2026 through 2035. - The report says the first year of the forecast period, 2026, is valued at USD 2.15 billion. - The outlook was published on Sept. 22, 2026.

The details: - Pathologist shortages are a central growth driver, with only 3% of United Kingdom histopathology departments said to have enough staff to meet clinical demand. - United States residency output has stayed roughly flat since 2010 even as biopsy volumes have increased. - Regulators have cleared several whole-slide imaging platforms for primary diagnosis, reducing the compliance uncertainty that had slowed procurement. - Dedicated procedure codes for digitized specimen consultation are turning telepathology into a reimbursed service in the United States. - The National Institutes of Health committed USD 150 million through its Bridge2AI program in 2025 to validate pathology algorithms against curated, bias-audited datasets. - Danaher, Roche and Philips have shifted substantial research and development spending toward digital pathology. - Vendors are increasingly bundling software subscriptions with hardware instead of selling only one-time equipment. - North America accounts for 44.5% of 2025 revenue, supported by reimbursement codes and an installed scanner base. - Asia-Pacific is forecast to grow fastest at 12.0% CAGR, led by China and India digitizing tertiary hospital networks. - Europe ranks second with USD 0.54 billion in 2025, supported by national screening programs and centralized pathology hubs in the Nordics and the United Kingdom. - The report’s product breakdown shows whole slide imaging scanners as the largest segment at 40.5% of 2025 revenue. - Image analysis and AI software is the fastest-growing product segment at 10.9% CAGR. - Brightfield imaging holds 79.1% of 2025 revenue, while fluorescence is the fastest-growing imaging technique at 11.3% CAGR. - Disease diagnosis is the largest application at 52.7% of 2025 revenue. - Telepathology and consultation is the fastest-growing application at 11.1% CAGR. - Hospitals and reference laboratories are the largest end-user group at 41.1% of 2025 revenue. - Pharmaceutical and biotechnology companies and CROs are the fastest-growing end-user segment at 11.2% CAGR. - The market is moderately concentrated, with the top five suppliers holding roughly 48% to 55% of revenue. - More than 40 vendors compete in software, while hardware is consolidating around four scanner platforms. - Leica Biosystems expanded its scanner-agnostic image management platform with third-party algorithm hosting in March 2024. - Roche Diagnostics extended its digital pathology software into companion diagnostic workflows in September 2024. - Koninklijke Philips has early primary-diagnosis clearance and enterprise imaging integration. - Hamamatsu Photonics is positioned around optics and research strength. - Sectra AB signed multi-hospital enterprise imaging agreements in June 2024 across the Nordics and the United Kingdom. - Paige released clinical-grade foundation models in November 2023 trained on multi-institution slide archives. - Ibex Medical Analytics announced expanded European deployments in May 2025 across private laboratory networks. - The U.S. Food and Drug Administration granted additional clearances in January 2024 for whole-slide imaging in primary diagnostic use. - Market Research Future says the market is also benefiting from archive monetization, real-world evidence use cases and spatial biology convergence.

Between the lines: - The market is shifting from hardware sales to recurring revenue. - Software and platform control appear to be becoming more valuable than scanner ownership alone. - Reimbursement is a key inflection point because it gives hospitals a way to pay for adoption through operating revenue rather than capital budgets. - The report suggests pharmaceutical buyers may become a disproportionately important growth engine because they spend more on software and image-based endpoints than typical clinical customers.

What's next: - Market Research Future expects subscription and per-slide pricing models to gain ground as vendors try to match revenue with throughput. - The report also sees growth in de-identified image archives linked to outcomes data for drug discovery and real-world evidence. - Emerging-market hub-and-spoke networks are expected to expand in places with severe pathologist shortages. - Spatial biology and more autonomous algorithms are likely to push scanner specs, software capability and pricing higher through 2035. - The report forecasts the market will keep expanding as pathology moves from glass slides to digital archives and AI-assisted diagnosis.